• FirefoxInstall the new Firefox »
  •  Dow Down0.58% Nasdaq Down0.26%

    Cumberland Pharmaceuticals, Inc. (CPIX)

    6.63 Up 0.23(3.59%) 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Cumberland Pharmaceuticals, Inc.
    2525 West End Avenue
    Suite 950
    Nashville, TN 37203
    United States - Map
    Phone: 615-255-0068
    Fax: 615-255-0094
    Website: http://www.cumberlandpharma.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:96

    Business Summary 

    Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States. The company’s principal products comprise Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. Its products also include Omeclamox-Pak, a triple therapy combination medication for the treatment of Helicobacter pylori infection and duodenal ulcer disease; and Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cumberland Pharmaceuticals, Inc.

    Corporate Governance 
    Cumberland Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2013 is 7. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 4; Compensation: 7.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. A. J. Kazimi MBA, 57
    Founder, Chairman, Chief Exec. Officer and Pres
    Mr. Richard S. Greene , 50
    Chief Financial Officer, Principal Accounting Officer and VP
    Mr. Leo Pavliv R.Ph., 54
    Chief Devel. Officer and Sr. VP of Operations
    Mr. James L. Herman , 60
    Chief Compliance Officer and VP of National Accounts
    Mr. Martin E. Cearnal , 70
    Chief Commercial Officer, Sr. VP and Director
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders